Saito S, Hontsu S, Hiraoka J, Yamanaka A, Fujioka N, Shimada D
Intern Med. 2024; 63(23):3209-3215.
PMID: 38658343
PMC: 11671183.
DOI: 10.2169/internalmedicine.3028-23.
Zhen L, Zhao X, Li W, Wu J, Shang H, Chen S
Front Neurol. 2024; 14:1259484.
PMID: 38187148
PMC: 10770254.
DOI: 10.3389/fneur.2023.1259484.
Menon D, Bril V
Drugs. 2022; 82(8):865-887.
PMID: 35639288
PMC: 9152838.
DOI: 10.1007/s40265-022-01726-y.
Alhaidar M, Abumurad S, Soliven B, Rezania K
J Clin Med. 2022; 11(6).
PMID: 35329925
PMC: 8950430.
DOI: 10.3390/jcm11061597.
Johnson S, Katyal N, Narula N, Govindarajan R
Med Sci Monit. 2021; 27:e933296.
PMID: 34707081
PMC: 8562011.
DOI: 10.12659/MSM.933296.
Local use of dexamethasone in the treatment of ocular myasthenia gravis.
Shi M, Ye Y, Zhou J, Qin A, Cheng J, Ren H
BMC Ophthalmol. 2020; 20(1):432.
PMID: 33115419
PMC: 7594471.
DOI: 10.1186/s12886-020-01697-2.
Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.
Lotan I, Hellmann M, Wilf-Yarkoni A, Steiner I
J Neurol. 2020; 268(12):4573-4586.
PMID: 33064188
DOI: 10.1007/s00415-020-10264-0.
Reappraisal of Oral Steroid Therapy for Myasthenia Gravis.
Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K
Front Neurol. 2020; 11:868.
PMID: 32982912
PMC: 7477376.
DOI: 10.3389/fneur.2020.00868.
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Lee I, Kuo H, Aban I, Cutter G, McPherson T, Kaminski H
Neurology. 2020; 95(6):e755-e766.
PMID: 32611638
PMC: 7455358.
DOI: 10.1212/WNL.0000000000010031.
Italian recommendations for the diagnosis and treatment of myasthenia gravis.
Evoli A, Antonini G, Antozzi C, DiMuzio A, Habetswallner F, Iani C
Neurol Sci. 2019; 40(6):1111-1124.
PMID: 30778878
DOI: 10.1007/s10072-019-03746-1.
Gender differences in prednisone adverse effects: Survey result from the MG registry.
Lee I, Kaminski H, McPherson T, Feese M, Cutter G
Neurol Neuroimmunol Neuroinflamm. 2018; 5(6):e507.
PMID: 30345333
PMC: 6192695.
DOI: 10.1212/NXI.0000000000000507.
The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis.
Xie Y, Li H, Sun L, Kusner L, Wang S, Meng Y
Front Neurol. 2017; 8:230.
PMID: 28620344
PMC: 5450020.
DOI: 10.3389/fneur.2017.00230.
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.
Guptill J, Soni M, Meriggioli M
Neurotherapeutics. 2015; 13(1):118-31.
PMID: 26510558
PMC: 4720661.
DOI: 10.1007/s13311-015-0398-y.
Surgical treatment for medically refractory myasthenic blepharoptosis.
Shimizu Y, Suzuki S, Nagasao T, Ogata H, Yazawa M, Suzuki N
Clin Ophthalmol. 2014; 8:1859-67.
PMID: 25278744
PMC: 4179829.
DOI: 10.2147/OPTH.S69883.
Frontalis sling procedure for ocular myasthenia gravis.
Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N
Clin Ophthalmol. 2012; 6:575-7.
PMID: 22553417
PMC: 3340122.
DOI: 10.2147/OPTH.S30612.
Fracture rate in patients with myasthenia gravis: the general practice research database.
Pouwels S, de Boer A, Javaid M, Hilton-Jones D, Verschuuren J, Cooper C
Osteoporos Int. 2012; 24(2):467-76.
PMID: 22531999
PMC: 3557375.
DOI: 10.1007/s00198-012-1970-5.
Complete Remission of Generalized Myasthenia Gravis by Corticosteroid Treatment Alone without Thymectomy.
Kataoka H, Furiya Y, Ueno S
Case Rep Neurol. 2011; 3(3):239-41.
PMID: 22121352
PMC: 3223032.
DOI: 10.1159/000333437.
Autoimmune neuromuscular disorders in childhood.
McMillan H, Darras B, Kang P
Curr Treat Options Neurol. 2011; 13(6):590-607.
PMID: 21912840
PMC: 3207132.
DOI: 10.1007/s11940-011-0146-5.
Current and emerging treatments for the management of myasthenia gravis.
Sathasivam S
Ther Clin Risk Manag. 2011; 7:313-23.
PMID: 21845054
PMC: 3150477.
DOI: 10.2147/TCRM.S14015.
Treatment of myasthenia gravis: focus on pyridostigmine.
Maggi L, Mantegazza R
Clin Drug Investig. 2011; 31(10):691-701.
PMID: 21815707
DOI: 10.2165/11593300-000000000-00000.